Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
Table 2
Injection history prior to aflibercept conversion.
Ranibizumab
Patients treated previously with only ranibizumab, (%)
14 (29.8%)
Prior injections, mean (±SD, range)
11.14 (±7.14, 3–26)
Bevacizumab
Patients treated previously with only bevacizumab, (%)
15 (31.9%)
Prior injections, mean (±SD, range)
10 (±5.29, 3–22)
Both
Patients treated previously with both, (%)
18 (38.3%)
Prior injections, mean (±SD, range)
12.5 (±5.57, 8–27)
All patients
Prior injections, mean (±SD, range)
11.3 (±5.96, 3–27)
Interval between 1st IVA and previous anti-VEGF, days (±SD, range)
